CN105250271A - Composition and application of composition in rhinitis-resistant medicine - Google Patents
Composition and application of composition in rhinitis-resistant medicine Download PDFInfo
- Publication number
- CN105250271A CN105250271A CN201510760811.6A CN201510760811A CN105250271A CN 105250271 A CN105250271 A CN 105250271A CN 201510760811 A CN201510760811 A CN 201510760811A CN 105250271 A CN105250271 A CN 105250271A
- Authority
- CN
- China
- Prior art keywords
- rhinitis
- composition
- compositions
- compound
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of organic synthesis and medicinal chemistry, in particular to a composition and an application of the composition in preparation of rhinitis-resistant medicine. According to the composition and a preparation method of the composition, pharmacology experiments show that the composition has the rhinitis-resistant effect and further has the value for developing the rhinitis-resistant medicine.
Description
Technical field
The present invention relates to organic synthesis and medicinal chemistry art, be specifically related to compositions, preparation method and its usage.
Background technology
Rhinitis is common clinical and frequently-occurring disease, and the generation of rhinitis is main relevant with anaphylaxis, belongs to the category of immune inflammation.At present, treatment rhinitis mainly adopt the antihistamine drug such as teldane or the Claritin such as tranilast, ketotifen, these medicines to the chronicity of rhinitis and recurrent exerbation curative effect poor or invalid.Therefore, definite ingredients, quality controllable and safely and efficiently micromolecular compound in development treatment of rhinitis medicine, there is potential value.
From natural product, find compound or lead compound and carry out structural modification and obtain its derivant, thus the potential drug obtaining high-efficiency low-toxicity there is important value most.
The Compound I that the present invention relates to is one and delivers (AyumiOhsakietal. in 2011,2011.SalviskinoneA, aditerpenewithanewskeletonfromSalviaprzewalskii.Tetrahed ronLetters52 (2011) 1375 – 1377) compound, we have carried out structural modification to Compound I, obtain two new derivants and compound III and compound IV, and prepared compositions by compound III and compound IV, and the anti-rhinitis activity of said composition is evaluated, it is active that it has anti-rhinitis.
Summary of the invention
The invention discloses a new compositions, said composition is made up of compound III and compound IV, and in said composition, the mass percent of compound III and compound IV is respectively 90% and 10%.
Compositions disclosed by the invention can make pharmaceutically acceptable salt or pharmaceutically acceptable carrier.
Pharmacodynamic experiment shows, compositions of the present invention has good anti-rhinitis effect.Pharmaceutically acceptable salt of the present invention has same drug effect.
Compositions 10mg/kg oral administration, raises inhibited to scratch nose, sneeze reaction and nasal cavity vascular permeability of rat caused by antigen (ovalbumin) and histamine, therefore, can be used for the medicine preparing treatment rhinitis.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation of embodiment 1 compound S alviskinoneA
Document (the AyumiOhsakietal. that the people such as the preparation method reference AyumiOhsaki of compound S alviskinoneA (I) deliver, 2011.SalviskinoneA, aditerpenewithanewskeletonfromSalviaprzewalskii.Tetrahed ronLetters52 (2011) 1375 – 1377) method.
The synthesis of the O-bromoethyl derivant (II) of embodiment 2SalviskinoneA
By Compound I (312mg, 1.00mmol) be dissolved in 15mL benzene, add in solution tetrabutyl ammonium bromide (TBAB) (0.08g), 1,50% sodium hydroxide solution of 2-Bromofume (3.760g, 20.00mmol) and 6mL.Mixture stirs 12h at 35 degrees Celsius.After 12h, reactant liquor is poured in frozen water, use dichloromethane extraction twice immediately, merge organic phase solution.Then use water and saturated common salt water washing 4 times successively to organic phase solution, then use anhydrous sodium sulfate drying, last concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:1.5, v/v), collects brown concentrated elution band and flings to the brown ceramic powder (327mg, 78%) that namely solvent obtains Compound II per.
1HNMR(500MHz,DMSO-d
6)δ6.63(s,1H),6.37(s,1H),5.81(s,1H),4.51(s,2H),3.84(s,1H),3.79(s,2H),2.15(s,1H),2.04(s,1H),1.91(s,1H),1.65(s,1H),1.39(s,3H),1.08(s,6H),0.99(s,6H).
13CNMR(125MHz,DMSO-d6)δ188.07(s),183.70(s),154.38(s),147.57(s),140.21(s),136.40(s),134.71(s),131.25(s),128.40(s),118.83(s),72.12(s),45.49(s),37.54(s),33.58(s),31.78(s),26.17(s),25.12(s),24.66(s),23.51(s),23.17(s),22.65(s).
HRMS(ESI)m/z[M+H]
+calcdforC
22H
28BrO
3:419.1222；found419.1220.
The synthesis of O-(imidazole radicals) ethyl derivative (III) of embodiment 3SalviskinoneA
Compound II per (209mg, 0.5mmol) is dissolved in the middle of 30mL acetonitrile, adds Anhydrous potassium carbonate (690mg wherein, 5.0mmol), potassium iodide (252mg, 1.5mmol) and imidazoles (870mg, 10mmol), mixture reflux 4h.After reaction terminates, reactant liquor is poured in 45mL frozen water, with equivalent dichloromethane extraction 3 times, merge organic facies.Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:0.2, v/v), collects brown concentrated elution band and flings to the Light brown solid (144.1mg, 71%) that namely solvent obtains compound III.
1HNMR(500MHz,DMSO-d6)δ7.91(s,1H),7.16(s,1H),6.65(d,J＝103.6Hz,2H),6.41(s,1H),5.76(s,1H),4.50(s,2H),4.39(s,2H),3.82(s,1H),2.05(s,1H),1.94(s,1H),1.87(s,1H),1.61(s,1H),1.30(s,3H),0.99(s,6H),0.90(s,6H).
13CNMR(125MHz,DMSO-d6)δ187.81(s),183.33(s),153.90(s),147.28(s),139.81(s),139.19(s),136.14(s),134.34(s),130.77(s),128.43(s),128.01(s),118.85(s),118.53(s),69.03(s),45.02(s),43.70(s),37.46(s),33.09(s),25.87(s),25.06(s),24.29(s),23.03(s),23.05(s),22.41(s).
HRMS(ESI):m/z[M+H]
+calcdforC
25H
31N
2O
3:407.2335；found:407.2331。
The synthesis of O-(triazolyl) ethyl derivative (IV) of embodiment 4SalviskinoneA
By Compound II per (209mg, 0.5mmol) be dissolved in the middle of 20mL acetonitrile, add Anhydrous potassium carbonate (345mg wherein, 2.5mmol), potassium iodide (84mg, 0.5mmol) and 1,2,3-triazole (2760mg, 40mmol), mixture reflux 4h.After reaction terminates, reactant liquor is poured in 20mL frozen water, with equivalent dichloromethane extraction 3 times, merge organic facies.Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:0.5, v/v), collects the yellow yellow powder (134.3mg, 66%) concentrating elution band namely to obtain compound IV.
1HNMR(500MHz,Chloroform-d1)δ8.37(s,1H),7.95(s,1H),6.35(s,1H),6.14(s,1H),5.35(s,1H),4.13(s,1H),4.42(d,J＝16.4Hz,3H),3.71(s,1H),2.13(s,1H),2.05(s,1H),1.81(s,1H),1.63(s,1H),1.30(s,3H),1.08(s,6H),0.97(s,6H).
13CNMR(125MHz,DMSO-d6)δ188.09(s),183.61(s),154.18(s),147.26(s),139.72(s),136.40(s),136.32(s),134.52(s),130.95(s),127.99(s),120.16(s),118.62(s),67.14(s),46.27(s),45.18(s),37.69(s),33.32(s),26.14(s),25.01(s),24.41(s),23.23(s),23.06(s),22.47(s).
HRMS(ESI):m/z[M+H]
+calcdforC
24H
30N
3O
3:408.2287；found:408.2282。
Embodiment 5 present composition causes the impact of rat allergic rhinitis on ovalbumin
Male SD rat, body weight 180 ~ 220g, lumbar injection ovalbumin 1mg and gel aluminum hydroxide 10mg, inject 1 time next day of thereafter, totally 7 times.Began from the 14th day, every day instills 1mg/ml ovalbumin normal saline solution 10ul at rat both sides nasal cavity, totally 7 times.Last is observed rat sneeze in 30 minutes at once and is wiped the number of times of nose after instiling, trial drug instils in ovalbumin last and orally to give for first 1 hour.
The preparation of compositions: loaded by the powder of 10mg compound IV crossing 200 order nets after crossing the powder of the 90mg compound III of 200 order nets and grinding after grinding to mix in tubule with cover and with turbine stirring instrument and namely obtain 100mg compositions, obtains the solution of compositions by the compositions of this 100mg of water dissolution during use.
From table 1, compositions (10mg/kg) obviously suppresses the sneeze of allergic rhinitis rat caused by ovalbumin and nose reaction of scratching.Compound III and compound IV act on without this.
Table 1 present composition causes the impact of rat allergic rhinitis to ovalbumin
* p<0.05, compares with matched group
Embodiment 6 present composition is on the impact of the rat rhinitis that histamine causes
Male SD rat, body weight 180 ~ 220g, orally to give after trial drug 1 hour, and both sides nasal cavity instillation 1M histamine normal saline solution 10ul, observes the number of times of rat sneeze and wiping nose in 30 minutes.
From table 2, the present composition (10mg/kg) obviously reduces the sneeze number of times of rhinitis rat caused by histamine, to nose reaction of scratching in suppression trend.Compound III and compound IV act on without this.
Table 2 present composition causes the impact of rat rhinitis to histamine
* p<0.05, compares with matched group
The impact that embodiment 7 present composition causes rat nasal cavity vascular permeability to raise on ovalbumin, histamine
Male SD rat, body weight 180 ~ 220g, observe with active sensitization rat and normal rat the nasal cavity vascular permeability that ovalbumin and histamine cause respectively to raise, the method of sensitization of rat is tested with allergic rhinitis, after initial immunity the 14th day, rats by intraperitoneal injection pentobarbital sodium 40mg/kg, after anesthesia from trachea to nasal intubation, be connected this intubate with constant flow pump after fixing (0.25ml/min0, with 37 DEG C of normal saline flushing nasal cavities 10 minutes, thereafter the blue normal saline solution 5ml/kg of rat tail vein injection 1%Evans, perfusate is collected 10 minutes after 3 minutes.At sensitized rats and normal rat, respectively containing ovalbumin 1mg/ml and histamine 40ug/ml in perfusate, the perfusate collected from nasal cavity through 1200 × g centrifugal 10 minutes, the Evans indigo plant concentration in 620nm place colorimetric determination supernatant, test medicine and antigen or histamine perfusion first 1 hour oral administration.
From table 3, the present composition (10mg/kg) obviously suppresses the nasal cavity vascular permeability of allergic rhinitis rat caused by ovalbumin.Compound III and compound IV act on without this.
The impact that table 3 present composition causes rat nasal cavity vascular permeability to raise on ovalbumin
* p<0.01, compares with matched group
From table 4, present composition 10mg/kg obviously reduces the nasal cavity vascular permeability of rat caused by histamine.Compound III and compound IV act on without this.
The impact that table 4 present composition causes rat nasal cavity blood flow permeability to raise on histamine
* p<0.01, compares with matched group
Conclusion: composition oral administration, raises have remarkable inhibitory action to scratch nose, sneeze reaction and nasal cavity vascular permeability of rat caused by antigen (ovalbumin) and histamine, therefore, can be used for the medicine preparing treatment rhinitis.Compound III and compound IV raise do not have remarkable inhibitory action to scratch nose, sneeze reaction and nasal cavity vascular permeabilitys of rat caused by antigen (ovalbumin) and histamine, therefore, are not useable for the medicine preparing treatment rhinitis.
The preparation of embodiment 8 composition tablet involved in the present invention
Get 2 grams of compositionss, add the customary adjuvant 18 grams preparing tablet, mixing, conventional tablet presses makes 100.
The preparation of embodiment 9 composition capsule involved in the present invention
Get 2 grams of compositionss, add prepare capsule customary adjuvant as starch 18 grams, mixing, encapsulatedly makes 100.
Claims (10)
1. a compositions, it is characterized by said composition and be made up of compound III and compound IV, in said composition, the mass percent of compound III and compound IV is respectively 90% and 10%,
2. the preparation method of compositions as claimed in claim 1, is characterized by: the powder of compound III and the powder of compound IV are respectively 90% and 10% according to mass percent and fully mix.
3. the application of compositions as claimed in claim 1 in anti-rhinitis medicament thing.
4. the application of compositions according to claim 3 in anti-rhinitis medicament thing, is characterized by: the rhinitis of described rhinitis caused by antigen.
5. the application of compositions according to claim 4 in anti-rhinitis medicament thing, is characterized by: described antigen is ovalbumin.
6. the application of compositions according to claim 5 in anti-rhinitis medicament thing, is characterized by: described compositions can suppress scratch caused by ovalbumin nose number of times and sneeze reaction.
7. the application of compositions according to claim 5 in anti-rhinitis medicament thing, is characterized by: described compositions can suppress the rising of nasal cavity vascular permeability caused by ovalbumin.
8. the application of compositions according to claim 3 in anti-rhinitis medicament thing, is characterized by: the rhinitis of described rhinitis caused by histamine.
9. the application of compositions according to claim 8 in anti-rhinitis medicament thing, is characterized by: described compositions can suppress scratch caused by histamine nose number of times and sneeze reaction.
10. the application of compositions according to claim 8 in anti-rhinitis medicament thing, is characterized by: described compositions can suppress the rising of nasal cavity vascular permeability caused by histamine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510760811.6A CN105250271A (en) | 2015-11-10 | 2015-11-10 | Composition and application of composition in rhinitis-resistant medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510760811.6A CN105250271A (en) | 2015-11-10 | 2015-11-10 | Composition and application of composition in rhinitis-resistant medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105250271A true CN105250271A (en) | 2016-01-20 |
Family
ID=55090410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510760811.6A Pending CN105250271A (en) | 2015-11-10 | 2015-11-10 | Composition and application of composition in rhinitis-resistant medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105250271A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108129442A (en) * | 2017-12-27 | 2018-06-08 | 常州南京大学高新技术研究院 | The miscellaneous source terpene piperazinyl of guava dialdehyde and tetrazole radical derivative composition are used to prepare anti-rhinitis medicament object |
-
2015
- 2015-11-10 CN CN201510760811.6A patent/CN105250271A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| AYUMI OHSAKI等: "salviskinone A, a diterpene with a new skeleton from salvia przewalskii", 《TETRAHEDRON LETTERS》 * |
| HIEN TRUNG TRINH 等: "Tanshinones isolated from the rhizome of Salvia miltiorrhiza inhibit passive cutaneous anaphylaxis reaction in mice", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
| 梅燕飞等: "丹参酮ⅡA 的药理作用及治疗应用研究进展", 《神经药理学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108129442A (en) * | 2017-12-27 | 2018-06-08 | 常州南京大学高新技术研究院 | The miscellaneous source terpene piperazinyl of guava dialdehyde and tetrazole radical derivative composition are used to prepare anti-rhinitis medicament object |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105287598A (en) | Composition and application of composition in medicine for resisting rhinitis | |
| CN104083379B (en) | The dimethylamine derivative of Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone is preparing the application in anti-rhinitis medicament thing | |
| CN104188980B (en) | O-(morpholinyl) ethyl derivative of Cleistanone Cleistanone, preparation method and its usage | |
| CN104402964B (en) | O-(imidazole radicals) ethyl derivative of Cleistanone, preparation method and its usage | |
| CN105250271A (en) | Composition and application of composition in rhinitis-resistant medicine | |
| CN105287568A (en) | Composition and application thereof to rhinitis resistant medicines | |
| CN105343080A (en) | Composition and application of composition in preparation of medicines for resisting rhinitis | |
| CN105343044A (en) | Composition and application thereof in anti-rhinitis drug | |
| CN105434413A (en) | Composition and application thereof to anti-rhinitis medicine | |
| CN104887662A (en) | Application of Daphmalenine A ramification to preparing rhinitis-resisting medicine | |
| CN105287557A (en) | Composition and application thereof to rhinitis resistant medicines | |
| CN105168222A (en) | Composition and application of composition to anti-rhinitis medicine | |
| CN105796561A (en) | Application of composition of piperazine-based and imidazole-based derivatives of virosaine A in rhinitis-resistant medicine | |
| CN105343091A (en) | Composition and application thereof in rhinitis resistant drugs | |
| CN104825468A (en) | Application of cleistanone O-(benzimidazolyl) ethyl derivative in preparation of anti-rhinitis drugs | |
| CN105395558A (en) | Composition and application of same to medicine resistant to rhinitis | |
| CN104814967A (en) | Application of cleistanthus sumatranus ketone O-(1H-tetrazole base) ethyl ramification to preparing rhinitis-resisting medicine | |
| CN105343099A (en) | Composition and application thereof in anti-rhinitis drug | |
| CN105232535A (en) | Composition and application thereof in anti-rhinitis drugs | |
| CN105055410A (en) | Composition 16080301030537 and application thereof in medicines of resisting rhinitis | |
| CN104873506A (en) | Application of O-(diethylamino) ethyl derivative of Daphmalenine A in preparation of anti-rhinitis drug | |
| CN106038544A (en) | Application of composition of Artalbic acid derivatives in preparation of anti-rhinitis drugs | |
| CN105998009A (en) | Application of composition of Salviskinone A benzimidazolyl and di(2-methylmercapto ethyl)amido derivatives in anti-rhinitis drugs | |
| CN106074512A (en) | The composition of Ah draw'sing Bick acid triazolyl and 1H tetrazole radical derivative is for preparing anti-rhinitis medicament thing | |
| CN105343082A (en) | Composition and application of composition in medicines for resisting acute renal failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160120 |
|
| WD01 | Invention patent application deemed withdrawn after publication |